FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950331809> ?p ?o ?g. }

• W2950331809 abstract "Background Canakinumab is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) older than 2 years. Objectives The aim of the German Biologics Registry (BiKeR) is the surveillance of JIA patients exposed to biologics. Methods Baseline demographics and disease activity parameters were documented. Efficacy was determined using the JADAS and the proposed criteria for inactive disease on medication. Safety assessments were based on reports of adverse events (AE). All reports have been coded according to MedDRA ®. Results 48 sJIA patients with 82.5 patient-years (PY) of exposure to Canakinumab were recorded in the German BiKeR registry. The total observation time (from date of first dose until last follow-up, censored, if another biologic was started) was calculated with 109.9 PY. The cohort treated with Canakinumab had experienced long disease duration of 2.9+/-3.8 years (mean +/- SD). 21 (44%) were pre-treated with methotrexate, 10 (21%) with Etanercept, 3 (6%) with Adalimumab, 18 (38%) with Anakinra and 19 (40%) with Tocilizumab. Concomitantly, 9 (18.8%) received methotrexate, 22 (45.8%) NSAIDs and 23 (48%) systemic corticosteroids. At last follow up upon treatment, 48%/44%/42%/38% of patients reached PedACR30/50/70/90 improvement. 8 patients (16.7%) had inactive disease according to the Wallace criteria. The median (IQR1-IQR3) JADAS10 score decreased from 12.6 (6.2-15.8) at baseline to 0.5 (0.0-2.8). During ongoing treatment, approximately 82% of patients achieved a JADAS defined minimal disease activity; while 64% reached a JADAS defined remission at last follow-up. 125 adverse events (AE) were recorded (114 events/100PY [95% CI 96-136]). Of these, 22 qualified as serious adverse events (SAE) (20/100PY [13-30]). 100 AEs were observed during exposure or up to 90 days follow up after the last exposure to Canakinumab (121/100PY [99-147]). 19 qualified as SAE (23/100PY [15-36]). Adverse Events of Special Interest were serious and medically important infection (n=4), cytopenia (n=4), macrophage activation syndrome (n=3). There was no opportunistic infection, intestinal perforation, anaphylaxis or other hypersensitivity, thrombotic event, evolving autoimmune disease, cardiac or cerebral event, bleeding, malignancy, or death. A total of 38 patients (79%) discontinued treatment, 8 (17%) due to lack or efficacy, 16 (33%) due to remission and 2 (4%) because of intolerance. Conclusion The current analysis adds to the established safety profile of Canakinumab and demonstrates that safety was comparable and consistent with the overall AE profile of Canakinumab in paediatric patients. MAS occurred in three sJIA patients and might be a JIA-associated feature. Infections were the most frequent AE, but only two serious infections were reported. No new safety signals specific to the paediatric population were identified for Canakinumab; the risk profile of Canakinumab remains positive for the approved paediatric indication sJIA. References [1] Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016Nov24;18(1):272 Acknowledgement The authors acknowledge all contributors to BIKER, patients, parents and study staff Disclosure of Interests Gerd Horneff: None declared, Eggert Lilienthal: None declared, Ralf Trauzeddel: None declared, Toni Hospach Speakers bureau: Chugai, Roche, Novartis, Tilmann Kallinich Grant/research support from: Novartis, Speakers bureau: Sobi, Roche, Novartis, CLB, Frank Dressler Paid instructor for: Abbvie, Pfizer, Novartis, Michaela Sailer-Hoeck: None declared, Gerd Ganser: None declared, Frank Weller-Heinemann: None declared, Georg Heubner: None declared, Andreas Urban: None declared, Michael Ruhlmann: None declared, Christoph Rietschel: None declared, Markus Hufnagel: None declared, Wolfgang Emminger: None declared, Ariane Klein: None declared" @default.
• W2950331809 created "2019-06-27" @default.
• W2950331809 creator A5010887077 @default.
• W2950331809 creator A5023555901 @default.
• W2950331809 creator A5028994250 @default.
• W2950331809 creator A5031193349 @default.
• W2950331809 creator A5033173364 @default.
• W2950331809 creator A5042586954 @default.
• W2950331809 creator A5050342158 @default.
• W2950331809 creator A5053719643 @default.
• W2950331809 creator A5053826746 @default.
• W2950331809 creator A5055322467 @default.
• W2950331809 creator A5061198096 @default.
• W2950331809 creator A5061594100 @default.
• W2950331809 creator A5064302794 @default.
• W2950331809 creator A5069187429 @default.
• W2950331809 creator A5074973060 @default.
• W2950331809 creator A5079998565 @default.
• W2950331809 date "2019-06-01" @default.
• W2950331809 modified "2023-09-25" @default.
• W2950331809 title "FRI0544 EFFICACY AND SAFETY OF CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS –EXPERIENCE USING DATA OF THE BIKER REGISTRY" @default.
• W2950331809 cites W2227962857 @default.
• W2950331809 cites W2339809952 @default.
• W2950331809 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1429" @default.
• W2950331809 hasPublicationYear "2019" @default.
• W2950331809 type Work @default.
• W2950331809 sameAs 2950331809 @default.
• W2950331809 citedByCount "0" @default.
• W2950331809 crossrefType "proceedings-article" @default.
• W2950331809 hasAuthorship W2950331809A5010887077 @default.
• W2950331809 hasAuthorship W2950331809A5023555901 @default.
• W2950331809 hasAuthorship W2950331809A5028994250 @default.
• W2950331809 hasAuthorship W2950331809A5031193349 @default.
• W2950331809 hasAuthorship W2950331809A5033173364 @default.
• W2950331809 hasAuthorship W2950331809A5042586954 @default.
• W2950331809 hasAuthorship W2950331809A5050342158 @default.
• W2950331809 hasAuthorship W2950331809A5053719643 @default.
• W2950331809 hasAuthorship W2950331809A5053826746 @default.
• W2950331809 hasAuthorship W2950331809A5055322467 @default.
• W2950331809 hasAuthorship W2950331809A5061198096 @default.
• W2950331809 hasAuthorship W2950331809A5061594100 @default.
• W2950331809 hasAuthorship W2950331809A5064302794 @default.
• W2950331809 hasAuthorship W2950331809A5069187429 @default.
• W2950331809 hasAuthorship W2950331809A5074973060 @default.
• W2950331809 hasAuthorship W2950331809A5079998565 @default.
• W2950331809 hasBestOaLocation W29503318091 @default.
• W2950331809 hasConcept C126322002 @default.
• W2950331809 hasConcept C187212893 @default.
• W2950331809 hasConcept C188313352 @default.
• W2950331809 hasConcept C197636746 @default.
• W2950331809 hasConcept C197934379 @default.
• W2950331809 hasConcept C199475168 @default.
• W2950331809 hasConcept C2777077863 @default.
• W2950331809 hasConcept C2777138892 @default.
• W2950331809 hasConcept C2777178219 @default.
• W2950331809 hasConcept C2777226972 @default.
• W2950331809 hasConcept C2777575956 @default.
• W2950331809 hasConcept C2779134260 @default.
• W2950331809 hasConcept C2779613421 @default.
• W2950331809 hasConcept C2779725882 @default.
• W2950331809 hasConcept C2780132546 @default.
• W2950331809 hasConcept C2781059491 @default.
• W2950331809 hasConcept C2781228260 @default.
• W2950331809 hasConcept C2909065710 @default.
• W2950331809 hasConcept C57658597 @default.
• W2950331809 hasConcept C71924100 @default.
• W2950331809 hasConcept C72563966 @default.
• W2950331809 hasConceptScore W2950331809C126322002 @default.
• W2950331809 hasConceptScore W2950331809C187212893 @default.
• W2950331809 hasConceptScore W2950331809C188313352 @default.
• W2950331809 hasConceptScore W2950331809C197636746 @default.
• W2950331809 hasConceptScore W2950331809C197934379 @default.
• W2950331809 hasConceptScore W2950331809C199475168 @default.
• W2950331809 hasConceptScore W2950331809C2777077863 @default.
• W2950331809 hasConceptScore W2950331809C2777138892 @default.
• W2950331809 hasConceptScore W2950331809C2777178219 @default.
• W2950331809 hasConceptScore W2950331809C2777226972 @default.
• W2950331809 hasConceptScore W2950331809C2777575956 @default.
• W2950331809 hasConceptScore W2950331809C2779134260 @default.
• W2950331809 hasConceptScore W2950331809C2779613421 @default.
• W2950331809 hasConceptScore W2950331809C2779725882 @default.
• W2950331809 hasConceptScore W2950331809C2780132546 @default.
• W2950331809 hasConceptScore W2950331809C2781059491 @default.
• W2950331809 hasConceptScore W2950331809C2781228260 @default.
• W2950331809 hasConceptScore W2950331809C2909065710 @default.
• W2950331809 hasConceptScore W2950331809C57658597 @default.
• W2950331809 hasConceptScore W2950331809C71924100 @default.
• W2950331809 hasConceptScore W2950331809C72563966 @default.
• W2950331809 hasLocation W29503318091 @default.
• W2950331809 hasOpenAccess W2950331809 @default.
• W2950331809 hasPrimaryLocation W29503318091 @default.
• W2950331809 isParatext "false" @default.
• W2950331809 isRetracted "false" @default.
• W2950331809 magId "2950331809" @default.
• W2950331809 workType "article" @default.